V 520

Drug Profile

V 520

Alternative Names: Ad5 HIV-1 gag; HIV vaccine - Merck & Co; MRKAd5; MRKAd5 env/gag/rev; MRKAd5 gag/pol/nef; MRKAd5 HIV-1 gag; V520

Latest Information Update: 25 Sep 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck & Co
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued HIV-1 infections

Most Recent Events

  • 22 Sep 2007 Discontinued - Phase-I for HIV-1 infections in Malawi (Injection)
  • 22 Sep 2007 Discontinued - Phase-I for HIV-1 infections in Thailand (Injection)
  • 22 Sep 2007 Discontinued - Phase-II for HIV-1 infections in Australia (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top